سعر براليونت 150مجم 2 قلم معبأ 1 مل 2024

Alirocumab 150 mg/1 ml solution for subcutaneous injection in pre-filled pens (Praluent) by Sanofi; pack of 2 pens.

• Reduce risk of major adverse cardiovascular events in adults at increased riskDailyMed (US NLM)
• Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolaemia, adults and children >=8 years with HeFH, and adults with HoFHDailyMed (US NLM)

• Common (>5% and more than placebo): injection site reactions and influenza (primary hypercholesterolaemia); myalgia (established CV disease).International label, same formulation · DailyMed (US NLM)

• History of serious hypersensitivity reaction to alirocumab or any excipient.International label, same formulation · DailyMed (US NLM)

• Hypersensitivity reactions including hypersensitivity vasculitis, angioedema and reactions requiring hospitalisation; discontinue if serious reactions occur.International label, same formulation · DailyMed (US NLM)

• Human data insufficient to evaluate drug-associated risk; as an IgG antibody, alirocumab crosses the placenta, increasingly near term.International label, same formulation · DailyMed (US NLM)
• No information on presence in human milk; weigh benefits of breastfeeding against clinical need.International label, same formulation · DailyMed (US NLM)